1
|
Ai L, Higashi M, Lee K, Liu Z, Jin L, Raja K, Mai Y, Jun T, Oh W, Beckmann A, Schadt E, Schadt Z, Wallsten R, Calay E, Kasarskis A, Pan Q, Schadt E, Wang X. AB0227 TREATMENT SEQUENCING PATTERNS AND COMPARATIVE EFFICACY IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM A REAL-WORLD SETTING. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundThe European League Against Rheumatism (EULAR)1 recently provided updated guidelines regarding the initiation and modification of disease-modifying antirheumatic drug (DMARD) therapy in patients with Rheumatoid Arthritis (RA). Therefore, real-world evidence studies are warranted to provide insights into first-line DMARD utilization and durability of response in the second-line setting.ObjectivesTo analyze RA treatment patterns in real-world data and compare durability of response between second-line DMARDs + anti-TNF (TNFi) therapies vs. TNFi monotherapy.MethodsElectronic health records (EHRs) from a large health system in the Northeast US were used to identify RA patients. Lines of therapy were defined based on confirmed prescriptions for DMARDs and TNFi therapies. Time to next treatment (TTNT) was the primary outcome to estimate durability of response. Time-to-event analyses were performed using Kaplan-Meier and log-rank test methods. In addition, a Cox Proportional-Hazards (CoxPH) model was used to evaluate covariates as independent predictors of disease progression.ResultsOur study cohort consisted of 8,040 patients who had at least one line of therapy for RA. Conventional synthetic DMARDs (csDMARDs) were the predominant first line of therapy in this dataset (71.3%), followed by TNFi alone (11.1%) or TNFi combined with csDMARD (9.1%) (Figure 1).For patients who had csDMARD as their first line of therapy, 22.93% progressed to second line treatment. Among them 36.2% patients were TNFi with or without in combination with csDMARDs. In the second-line, TNFi + csDMARDs were associated with a longer TTNT (median time: 13.1 months vs 6.1 months, P < 0.005) compared to TNFi monotherapy. The multiple variable CoxPH model (adjusted for age, gender, and race) demonstrated that second-line TNFi + csDMARDs had a lower hazard rate when compared to TNFi monotherapy (HR = 0.74, 95% CI: 0.36 - 1.12, p < 0.005).ConclusionWe demonstrated the first comprehensive treatment sequencing patterns in RA from a real-world setting. As a second-line therapy for patients with inadequate response to csDMARDS, the TNFi + csDMARDs combination may improve duration of response when compared to TNFi monotherapy. Results from this study will inform future sequencing strategies to improve patient outcomes.References[1]Smolen, Josef S., Robert B. M. Landewé, Johannes W. J. Bijlsma, Gerd R. Burmester, Maxime Dougados, Andreas Kerschbaumer, Iain B. McInnes, et al. 2020. “EULAR Recommendations for the Management of Rheumatoid Arthritis with Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2019 Update.” Annals of the Rheumatic Diseases 79 (6): 685–99.Disclosure of InterestsLei Ai: None declared, Mitchell Higashi: None declared, Kyeryoung Lee: None declared, Zongzhi Liu: None declared, Lan Jin: None declared, Kalpana Raja: None declared, Yun Mai: None declared, Tomi Jun: None declared, William Oh Consultant of: JanssenPfizer, Aviva Beckmann: None declared, Emilio Schadt: None declared, Zachary Schadt: None declared, Rick Wallsten: None declared, Ediz Calay: None declared, Andrew Kasarskis: None declared, Qi Pan: None declared, Eric Schadt Speakers bureau: Eli Lilly, Consultant of: SAB of Eli LillyCelgene, Xiaoyan Wang: None declared
Collapse
|
2
|
Mack P, Klein M, Ayers K, Uzilov A, Zhou X, Corrigan D, Dietz M, Fink M, Guin S, Kip N, Rossi M, Oh W, Hantash F, Newman S, Schadt E, Chen R, Hirsch F. 1271P Molecular driver mutations in never-smokers with lung adenocarcinoma. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1873] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Hwang J, Choi S, Oh W, Chang J, Na D. Intracerebroventricular transplantation of human umbilical cord blood derived mesenchymal stem cells attenuates symptoms of repetitive mild traumatic brain injury (RM TBI). Cytotherapy 2017. [DOI: 10.1016/j.jcyt.2017.02.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Stock R, Sfakianos J, Oh W, Stone N. Prostate-Specific Antigen Doubling Time Posttreatment Is the Most Significant Predictor of Survival Following the Brachytherapy Management of Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2016. [DOI: 10.1016/j.ijrobp.2016.06.1216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Oh W, Devonald M, Gardner D, Mahajan R, Harvey D, Sharman A, Mafrici B, Rigby M, Welham S. Micronutrient loss in renal replacement therapy for acute kidney injury. Crit Care 2015. [PMCID: PMC4471419 DOI: 10.1186/cc14380] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
6
|
Kim M, Jin H, Bae Y, Yang Y, Oh W, Choi S. Angiopoietin-1 of umbilical cord blood-derived mesenchymal stem cells inhibits lipopolysaccharide-induced inflammation. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Hong Y, Choi S, Yang Y, Oh W, Jeon E. Drug a enhances the immunosuppressive properties of human umbilical cord blood-derived mecenchymal stem cells. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Seon M, Lee M, Kim D, Lee K, Yang Y, Oh W, Choi S, Kwon S. The effects of microscale and nanoscale patterns on the proliferation of umbilical cord blood-derived mesenchymal stem cells. Cytotherapy 2014. [DOI: 10.1016/j.jcyt.2014.01.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Oh W, Venkata UC, Wang L, Reese E, Yee T, Kochukoshy T, Tsao C, Galsky M, Zhu J, Gong Y. MC13-0070 Whole blood RNA signature as prognostic and predictive biomarker in genitourinary malignancies. Eur J Cancer 2013. [DOI: 10.1016/s0959-8049(13)70178-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Oh W, Morris HF. A simple method to fabricate stabilized record bases: a modified approach using casting wax for the borders. Eur J Prosthodont Restor Dent 2013; 21:2-4. [PMID: 23682502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Retention and stability of a record base is often compromised in the mouth because of blockout procedures performed before adapting a record base material on a definitive cast. This article presents a technique of fabricating a stable and retentive record base, in which a definitive cast does not receive a blockout procedure so that the record base engages the facial undercuts in the cast by means of a green coloured inlay casting wax.
Collapse
|
11
|
Lee SH, Lee MW, Yoo KH, Kim DS, Son MH, Sung KW, Cheuh H, Choi SJ, Oh W, Yang YS, Koo HH. Co-transplantation of third-party umbilical cord blood-derived MSCs promotes engraftment in children undergoing unrelated umbilical cord blood transplantation. Bone Marrow Transplant 2013; 48:1040-5. [DOI: 10.1038/bmt.2013.7] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2012] [Revised: 01/05/2013] [Accepted: 01/10/2013] [Indexed: 12/11/2022]
|
12
|
Morris BH, Tyson JE, Stevenson DK, Oh W, Phelps DL, O’Shea TM, McDavid GE, Van Meurs KP, Vohr BR, Grisby C, Yao Q, Kandefer S, Wallace D, Higgins RD. Efficacy of phototherapy devices and outcomes among extremely low birth weight infants: multi-center observational study. J Perinatol 2013; 33:126-33. [PMID: 22499082 PMCID: PMC3570170 DOI: 10.1038/jp.2012.39] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Evaluate the efficacy of phototherapy (PT) devices and the outcomes of extremely premature infants treated with those devices. STUDY DESIGN This substudy of the National Institute of Child Health and Human Development Neonatal Research Network PT trial included 1404 infants treated with a single type of PT device during the first 24±12 h of treatment. The absolute (primary outcome) and relative decrease in total serum bilirubin (TSB) and other measures were evaluated. For infants treated with one PT type during the 2-week intervention period (n=1223), adjusted outcomes at discharge and 18 to 22 months corrected age were determined. RESULT In the first 24 h, the adjusted absolute (mean (±s.d.)) and relative (%) decrease in TSB (mg dl(-1)) were: light-emitting diodes (LEDs) -2.2 (±3), -22%; Spotlights -1.7 (±2), -19%; Banks -1.3 (±3), -8%; Blankets -0.8 (±3), -1%; (P<0.0002). Some findings at 18 to 22 months differed between groups. CONCLUSION LEDs achieved the greatest initial absolute reduction in TSB but were similar to Spots in the other performance measures. Long-term effects of PT devices in extremely premature infants deserve rigorous evaluation.
Collapse
Affiliation(s)
- BH Morris
- Department of Neonatology, Trinity Mother Frances Health System, Tyler, TX, USA
| | - JE Tyson
- Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX, USA
| | - DK Stevenson
- Stanford University School of Medicine, Palo Alto, CA, USA
| | - W Oh
- Department of Pediatrics, Women and Infants Hospital, Brown University, Providence, RI, USA
| | - DL Phelps
- University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - TM O’Shea
- Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - GE McDavid
- Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX, USA
| | - KP Van Meurs
- Stanford University School of Medicine, Palo Alto, CA, USA
| | - BR Vohr
- Department of Pediatrics, Women and Infants Hospital, Brown University, Providence, RI, USA
| | - C Grisby
- Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
| | - Q Yao
- Statistics and Epidemiology Unit, RTI International, Research Triangle Park, NC, USA
| | - S Kandefer
- Statistics and Epidemiology Unit, RTI International, Research Triangle Park, NC, USA
| | - D Wallace
- Statistics and Epidemiology Unit, RTI International, Research Triangle Park, NC, USA
| | - RD Higgins
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
13
|
Tyson JE, Pedroza C, Langer J, Green C, Morris B, Stevenson D, Van Meurs KP, Oh W, Phelps D, O'Shea M, McDavid GE, Grisby C, Higgins R. Does aggressive phototherapy increase mortality while decreasing profound impairment among the smallest and sickest newborns? J Perinatol 2012; 32:677-84. [PMID: 22652561 PMCID: PMC3558278 DOI: 10.1038/jp.2012.64] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE Aggressive phototherapy (AgPT) is widely used and assumed to be safe and effective for even the most immature infants. We assessed whether the benefits and hazards for the smallest and sickest infants differed from those for other extremely low-birth-weight (ELBW; ≤ 1000 g) infants in our Neonatal Research Network trial, the only large trial of AgPT. STUDY DESIGN ELBW infants (n=1974) were randomized to AgPT or conservative phototherapy at age 12 to 36 h. The effect of AgPT on outcomes (death, impairment, profound impairment, death or impairment (primary outcome), and death or profound impairment) at 18 to 22 months of corrected age was related to BW stratum (501 to 750 g; 751 to 1000 g) and baseline severity of illness using multilevel regression equations. The probability of benefit and of harm was directly assessed with Bayesian analyses. RESULT Baseline illness severity was well characterized using mechanical ventilation and FiO(2) at 24 h age. Among mechanically ventilated infants ≤ 750 g BW (n=684), a reduction in impairment and in profound impairment was offset by higher mortality (P for interaction <0.05) with no significant effect on composite outcomes. Conservative Bayesian analyses of this subgroup identified a 99% (posterior) probability that AgPT increased mortality, a 97% probability that AgPT reduced impairment, and a 99% probability that AgPT reduced profound impairment. CONCLUSION Findings from the only large trial of AgPT suggest that AgPT may increase mortality while reducing impairment and profound impairment among the smallest and sickest infants. New approaches to reduce their serum bilirubin need development and rigorous testing.
Collapse
Affiliation(s)
- J E Tyson
- Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Abstract
OBJECTIVE The study's objective was to compare hematocrit (Hct) levels at 36 to 48 h of age in term infants delivered by cesarean section exposed to immediate cord clamping or umbilical cord milking (UCM). STUDY DESIGN In this randomized controlled trial, 24 women scheduled for elective cesarean section were randomized to either immediate clamping (<10 s) or UCM (milked × 5 by the obstetrical provider) at birth. RESULT All subjects received their allocated intervention. The milking group had a smaller placental residual blood volume (13.2±5.6 vs 19.2±5.4 ml kg(-1), P=0.01) and higher Hct levels at 36 to 48 h (57.5±6.6 vs 50.0±6.4 %, P=0.01). Five infants (42%) in the immediate group had a Hct of ≤47%, indicative of anemia. CONCLUSION UCM results in placental transfusion in term infants at the time of elective cesarean section with higher Hct levels at 36 to 48 h of age.
Collapse
|
15
|
Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, Kim SM, Yoo YJ, Lee EH, Choi SJ, Seo SW, Lee JI, Na DL, Yang YS, Oh W, Chang JW. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ 2011; 19:680-91. [PMID: 22015609 PMCID: PMC3307982 DOI: 10.1038/cdd.2011.140] [Citation(s) in RCA: 143] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Presently, co-culture of human umbilical cord blood mesenchymal stem cells (hUCB-MSCs) with BV2 microglia under amyloid-β42 (Aβ42) exposure induced a reduction of Aβ42 in the medium as well as an overexpression of the Aβ-degrading enzyme neprilysin (NEP) in microglia. Cytokine array examinations of co-cultured media revealed elevated release of soluble intracellular adhesion molecule-1 (sICAM-1) from hUCB-MSCs. Administration of human recombinant ICAM-1 in BV2 cells and wild-type mice brains induced NEP expression in time- and dose-dependent manners. In co-culturing with BV2 cells under Aβ42 exposure, knockdown of ICAM-1 expression on hUCB-MSCs by small interfering RNA (siRNA) abolished the induction of NEP in BV2 cells as well as reduction of added Aβ42 in the co-cultured media. By contrast, siRNA-mediated inhibition of the sICAM-1 receptor, lymphocyte function-associated antigen-1 (LFA-1), on BV2 cells reduced NEP expression by ICAM-1 exposure. When hUCB-MSCs were transplanted into the hippocampus of a 10-month-old transgenic mouse model of Alzheimer's disease for 10, 20, or 40 days, NEP expression was increased in the mice brains. Moreover, Aβ42 plaques in the hippocampus and other regions were decreased by active migration of hUCB-MSCs toward Aβ deposits. These data suggest that hUCB-MSC-derived sICAM-1 decreases Aβ plaques by inducing NEP expression in microglia through the sICAM-1/LFA-1 signaling pathway.
Collapse
Affiliation(s)
- J-Y Kim
- Biomedical Research Institute, MEDIPOST Co. Ltd., Seoul 137-874, Republic of Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Cho S, Ahn M, Yu I, Lee S, Yoon H, Oh S, Ku D, Oh D, Jhang H, Oh W, Kim D, Lee H. R&D activities on helium cooled solid breeder TBM in Korea. Fusion Engineering and Design 2010. [DOI: 10.1016/j.fusengdes.2010.04.063] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Oh W, Lee EW, Lee D, Yang MR, Ko A, Yoon CH, Lee HW, Bae YS, Choi CY, Song J. Hdm2 negatively regulates telomerase activity by functioning as an E3 ligase of hTERT. Oncogene 2010; 29:4101-12. [PMID: 20453884 DOI: 10.1038/onc.2010.160] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
In this study, we identified posttranslational regulation of human telomerase reverse-transcriptase (hTERT) by the E3 ligase Hdm2. The telomerase activity generated by exogenous hTERT in U2OS cells was reduced on adriamycin treatment. The overexpressed levels of hTERT were also decreased under the same conditions. These processes were reversed by treatment with a proteasome inhibitor or depletion of Hdm2. Furthermore, intrinsic telomerase activity was increased in HCT116 cells with ablation of Hdm2. Immunoprecipitation analyses showed that hTERT and Hdm2 bound to each other in multiple domains. Ubiquitination analyses showed that Hdm2 could polyubiquitinate hTERT principally at the N-terminus, which was further degraded in a proteasome-dependent manner. An hTERT mutant with all five lysine residues at the N-terminus of hTERT that mutated to arginine became resistant to Hdm2-mediated ubiquitination and degradation. In U2OS cells, depletion of Hdm2 or addition of the Hdm2-resistant hTERT mutant strengthened the cellular protective effects against apoptosis. Similar results were obtained with the Hdm2-stable H1299 cell line. These observations indicate that Hdm2 is an E3 ligase of hTERT.
Collapse
Affiliation(s)
- W Oh
- Department of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Oh W, Stevenson DK, Tyson JE, Morris BH, Ahlfors CE, Bender GJ, Wong RJ, Perritt R, Vohr BR, Van Meurs KP, Vreman HJ, Das A, Phelps DL, O'Shea TM, Higgins RD. Influence of clinical status on the association between plasma total and unbound bilirubin and death or adverse neurodevelopmental outcomes in extremely low birth weight infants. Acta Paediatr 2010; 99:673-678. [PMID: 20105142 DOI: 10.1111/j.1651-2227.2010.01688.x] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
OBJECTIVES To assess the influence of clinical status on the association between total plasma bilirubin and unbound bilirubin on death or adverse neurodevelopmental outcomes at 18-22 months corrected age in extremely low birth weight infants. METHOD Total plasma bilirubin and unbound bilirubin were measured in 1101 extremely low birth weight infants at 5 +/- 1 days of age. Clinical criteria were used to classify infants as clinically stable or unstable. Survivors were examined at 18-22 months corrected age by certified examiners. Outcome variables were death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss, and death prior to follow-up. For all outcomes, the interaction between bilirubin variables and clinical status was assessed in logistic regression analyses adjusted for multiple risk factors. RESULTS Regardless of clinical status, an increasing level of unbound bilirubin was associated with higher rates of death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss and death before follow-up. Total plasma bilirubin values were directly associated with death or neurodevelopmental impairment, death or cerebral palsy, death or hearing loss, and death before follow-up in unstable infants, but not in stable infants. An inverse association between total plasma bilirubin and death or cerebral palsy was found in stable infants. CONCLUSIONS In extremely low birth weight infants, clinical status at 5 days of age affects the association between total plasma bilirubin and death or adverse neurodevelopmental outcomes at 18-22 months of corrected age. An increasing level of UB is associated a higher risk of death or adverse neurodevelopmental outcomes regardless of clinical status. Increasing levels of total plasma bilirubin are directly associated with increasing risk of death or adverse neurodevelopmental outcomes in unstable, but not in stable infants.
Collapse
Affiliation(s)
- W Oh
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - D K Stevenson
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - J E Tyson
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - B H Morris
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - C E Ahlfors
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - G Jesse Bender
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - R J Wong
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - R Perritt
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - B R Vohr
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - K P Van Meurs
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - H J Vreman
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - A Das
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - D L Phelps
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - T Michael O'Shea
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| | - R D Higgins
- Warren Alpert Medical School of Brown University, RI, USAStanford University, Palo Alto, CAUniversity of Texas, Houston, TX, USAZF Diagnostics Vashon, WA, USAResearch Triangle International, RTI, NC, USAUniversity of Rochester, Rochester, NY, USAWake Forest University Winston-Salem, NC, USANICHD, Bethesda, MD, USA
| |
Collapse
|
19
|
Vinson J, Mathew P, Beer TM, Carducci MA, Oh W, Small E, Wilding G, Higano C, Hussain M, Scher HI. Prostate cancer clinical trials consortium: A multicenter mechanism for the rapid design, development, and implementation of early phase clinical trials. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16065 Background: Leading investigators in prostate cancer have hypothesized that clinical trials (CT) are optimally conducted as multicenter studies. To test this, the Prostate Cancer Clinical Trials Consortium (PCCTC) was formed with support from the Prostate Cancer Foundation (PCF) and the Department of Defense Clinical Consortium Award (DOD). Since the PCCTC's inception in 2006, members have cooperatively designed, carried out, and evaluated phase 1 and 2 multicenter studies in prostate cancer. Methods: PCF and DOD awards support a consortium of 13 cancer research centers. Memorial Sloan-Kettering Cancer Center serves as the coordinating center and is charged with creating an infrastructure to conduct early phase, multicenter trials. Annually, each participating center is required to introduce at least one CT for consideration by the PCCTC and accrue at least 35 patients to PCCTC studies. Investigators meet face-to-face twice per year to discuss the PCCTC's progress, and hold monthly conference calls to discuss scientific objectives, trial design, and ongoing studies. Results: Since inception, the PCCTC has expanded from 8 to 13 leading research centers. Through September 2008, it has opened 47 trials and accrued 1,282 patients at member sites. Members utilize a CT management system for protocol tracking, electronic data capture, and data storage. A legal framework has been instituted, and standard operating procedures, administrative structure, editorial support, centralized budgeting, and mechanisms for scientific review have been established. Each year, the number of trials presented and patients accrued increases, and three concepts have progressed to the next phase of clinical testing. Conclusions: The PCCTC fulfills a congressional directive to create a CT instrument dedicated to rapid accrual to early-phase, multicenter studies in prostate cancer. The member institutions have built a shared administrative, informatics, legal, financial, statistical, and scientific infrastructure to support this endeavor. As the PCCTC has expanded and taken an increasingly active role in designing and evaluating protocols, clinical trials continue to open and accrue in excess of federally mandated goals. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Vinson
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - P. Mathew
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - T. M. Beer
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - M. A. Carducci
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - W. Oh
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - E. Small
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - G. Wilding
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - C. Higano
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - M. Hussain
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| | - H. I. Scher
- Prostate Cancer Clinical Trials Consortium; Memorial Sloan-Kettering Cancer Center, New York, NY; M. D. Anderson Cancer Center, Houston, TX; Oregon Health & Science University, Portland, OR; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Dana-Farber Cancer Institute, Boston, MA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Wisconsin Carbone Cancer Center, Madison, WI; University of Washington, Seattle, WA; University of Michigan
| |
Collapse
|
20
|
Choueiri TK, Regan M, Oh W, Clement J, Amato A, McDermott D, Cho D, Atkins M, Signoretti S. Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e16067] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e16067 Background: Tumor Carbonic Anhydrase IX (CAIX) expression and histologic features can predict outcome in patients with metastatic renal cell carcinoma (mRCC) treated with immunotherapy. We sought to investigate the prognostic and predictive utility of such features in patients receiving VEGF-targeted therapy. Methods: We identified 118 patients with mRCC initiating first- line VEGF-targeted therapy including 94 with clinical data, clear cell histology and available tissue. Tumors were evaluated for specific histologic features and for CAIX expression by immunohistochemistry using the MN75 antibody. The relationship between these pathology findings and tumor shrinkage and other treatment outcomes was assessed. Results: Higher tumor clear cell component was independently associated with greater tumor shrinkage (p=0.02), response (p=0.02) and treatment duration (p=0.02). Patients with high vs. low tumor CAIX expression had mean tumor shrinkages of -12% vs. -5%, respectively (p=.38). There was heterogeneity in tumor responsiveness to sunitinib or sorafenib according to CAIX status (p=0.055 for interaction): mean shrinkage was -17% vs. -25% (mean difference +8%, 95% CI -14% to +31%) for sunitinib-treated patients with high vs. low tumor CAIX expression compared to -13% vs. +9% (mean difference -22%, 95% CI -42% to -1%) for sorafenib-treated patients. Conclusions: Patients with higher clear cell component in their tumors are likely to experience superior clinical benefit from VEGF-targeted therapy. Although CAIX expression was not found to be of prognostic value in patients with clear cell mRCC treated with VEGF-targeted therapy, it may be a predictive biomarker for response to sorafenib treatment. [Table: see text]
Collapse
Affiliation(s)
- T. K. Choueiri
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - M. Regan
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - W. Oh
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - J. Clement
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - A. Amato
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - D. McDermott
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - D. Cho
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - M. Atkins
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| | - S. Signoretti
- Dana- Faber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
21
|
Wadhawan R, Oh W, Perritt R, Laptook AR, Poole K, Wright LL, Fanaroff AA, Duara S, Stoll BJ, Goldberg R. Association between early postnatal weight loss and death or BPD in small and appropriate for gestational age extremely low-birth-weight infants. J Perinatol 2007; 27:359-64. [PMID: 17443198 DOI: 10.1038/sj.jp.7211751] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE To examine the association between weight loss during the first 10 days of life and the incidence of death or bronchopulmonary dysplasia (BPD) in small for gestational age (SGA) and appropriate for gestational age (AGA) extremely low-birth-weight infants. DESIGN/METHODS This is a retrospective analysis of a cohort of ELBW (birth weight <1000 g) infants from the NICHD Neonatal Research Network's database. The cohort consisted of 9461 ELBW infants with gestational age of 24-29 weeks, admitted to Network's participating centers during calendar years 1994-2002 and surviving at least 72 h after birth. The cohort was divided into two groups, 1248 SGA (with birth weight below 10th percentile for gestational age) and 8213 AGA (with birth weight between 10th and 90th percentile) infants. We identified infants with or without weight loss during the first 10 days of life, which we termed as 'early postnatal weight loss' (EPWL). Univariate analyses were used to predict whether EPWL was related to the primary outcome, death or BPD, within each birth weight/gestation category (SGA or AGA). BPD and death were also analyzed separately in relation to EPWL. Logistic regression analysis was done to evaluate the risk of death or BPD in SGA and AGA groups, controlling for maternal and neonatal demographic and clinical factors found to be significant by univariate analysis. RESULTS SGA ELBW infants had a lower prevalence of EPWL as compared with AGA ELBW infants (81.2 vs 93.7%, respectively, P<0.001). In AGA infants, univariate analysis showed that death or BPD rate was lower in the group of infants with EPWL compared with infants without EPWL (53.4 vs 74.3%, respectively, P<0.001). The BPD (47.2 vs 64%, P<0.001) and death (13.8 vs 32.9%, P<0.001) rate were similarly lower in the EPWL group. The risk-adjusted odds ratios (ORs) showed that EPWL was associated with lower rate of death or BPD (OR 0.47, 95% CI: 0.37-0.60). In SGA infants, on univariate analysis, a similar association between EPWL and outcomes was seen as shown in AGA infants: death or BPD (55.9 vs 75.2%, P<0.001), BPD rate (48.3 vs 62.1%, P=0.002) and rate death (19 vs 40.8%, P<0.001) for those with or without EPWL, respectively. Multiple logistic regression showed that as in AGA ELBW infants, EPWL was associated with lower risk for death or BPD (OR 0.60, 95% CI: 0.41-0.89) among SGA infants. CONCLUSIONS SGA infants experienced less EPWL when compared with their AGA counterparts. EPWL was associated with a lower risk of death or BPD in both ELBW AGA and SGA infants. These data suggest that clinicians who consider the association between EPWL and risk of death or BPD should do so independent of gestation/birth weight status.
Collapse
Affiliation(s)
- R Wadhawan
- Department of Pediatrics, All Childrens' Hospital, St. Petersburg, FL 33701, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Boudoux C, Yun S, Oh W, White W, Iftimia N, Shishkov M, Bouma B, Tearney G. Rapid wavelength-swept spectrally encoded confocal microscopy. Opt Express 2005; 13:8214-21. [PMID: 19498851 DOI: 10.1364/opex.13.008214] [Citation(s) in RCA: 64] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Spectrally encoded confocal microscopy (SECM) is a technique that allows confocal microscopy to be performed through the confines of a narrow diameter optical fiber probe. We present a novel scheme for performing SECM in which a rapid wavelength swept source is used. The system allows large field of view images to be acquired at rates up to 30 frames/second. Images of resolution targets and tissue specimens acquired ex vivo demonstrate high lateral (1.4 mum) and axial (6 mum) resolution. Imaging of human skin was performed in vivo at depths of up to 350 mum, allowing cellular and sub-cellular details to be visualized in real time.
Collapse
|
23
|
Lee B, Oh W, Yoon J, Hwang Y, Kim J, Landes BG, Quintana JP, Ree M. Scattering Studies of Nanoporous Organosilicate Thin Films Imprinted with Reactive Star Porogens. Macromolecules 2005. [DOI: 10.1021/ma0501951] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- B. Lee
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - W. Oh
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - J. Yoon
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - Y. Hwang
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - J. Kim
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - B. G. Landes
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - J. P. Quintana
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| | - M. Ree
- National Research Lab for Polymer Synthesis & Physics, Pohang Accelerator Laboratory, Center for Integrated Molecular Systems, Department of Chemistry, Polymer Research Institute, and Division of Molecular and Life Sciences, and School of Environmental Science & Engineering, Pohang University of Science & Technology, Pohang 790-784, Republic of Korea; Department of Analytical Sciences-Materials Characterization, 1897 Building, Dow Chemical Company, Midland, Michigan 48667; and DND-CAT Synchrotron
| |
Collapse
|
24
|
Michaelson MD, Gilligan T, Oh W, Kantoff P, Taplin ME, Izquierdo MA, Flores L, Smith MR. Phase II study of three hour, weekly infusion of trabectedin (ET-743) in men with metastatic, androgen-independent prostate carcinoma (AIPC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4517] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. D. Michaelson
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - T. Gilligan
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - W. Oh
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - P. Kantoff
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - M.-E. Taplin
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - M. A. Izquierdo
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - L. Flores
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| | - M. R. Smith
- MA Gen Hosp, Boston, MA; Dana-Farber Cancer Inst, Boston, MA; PharmaMar SA, Madrid, Spain
| |
Collapse
|
25
|
Abstract
Background Whether umbilical cord blood (UCB) serves as a source of mesenchymal stem/progenitor cells (MSPC) is controversial. MSPC are the best candidates for cellular therapy of orthopedic skeletal tissues. In order to explore the possibility of UCB as a useful source of MSPC, we identified, expanded in culture, and characterized MSPC from UCB harvests on a large scale. Methods Mononuclear cells isolated from UCB harvests (n=411) were cultured in media supplemented with 10% FBS. MSPC-like cells cultured from each UCB harvest were expanded ex vivo by successive subcultivation. UCB harvests with a more than 1000-fold expanding capacity (n=9) were examined for surface Ag phenotypes and in vitro differentiation potentials into osteogenic, chondrogenic and adipogenic lineages. Results Ninety-five out of a total of 411 UCB units (23.1%) generated MSPC-like cells during cultivation. Nine UCB units (2.2%) yielded MSPC with more than 1000-fold expansion capacity. These cells positively expressed MSPC-related Ag, but did not express myeloid, histocompatibility or endothelial Ag. These cells also possessed multiple capacities for osteogenic, chondrogenic and adipogenic differentiation. Discussion Although the incidence of UCB harvests producing MSPC in culture was low, some of them showed a more than 1000-fold expanding capacity, which is enough in cell numbers to be an allogeneic source for cellular therapy. Our results may encourage the use of UCB as an attractive target for allogeneic cellular therapeutic options in tissue engineering.
Collapse
Affiliation(s)
- S-E Yang
- Department of Research and Development for Cellular Therapy, Medipost Biomedical Research Institute, Yongin, Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Hintz SR, Poole WK, Wright LL, Fanaroff AA, Kendrick DE, Laptook AR, Goldberg R, Duara S, Stoll BJ, Oh W. Changes in mortality and morbidities among infants born at less than 25 weeks during the post-surfactant era. Arch Dis Child Fetal Neonatal Ed 2005; 90:F128-33. [PMID: 15724036 PMCID: PMC1721837 DOI: 10.1136/adc.2003.046268] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVES To compare mortality and death or major morbidity (DOMM) among infants <25 weeks estimated gestational age (EGA) born during two post-surfactant era time periods. STUDY DESIGN AND PATIENTS Comparative cohort study of very low birthweight (501-1500 g) infants <25 weeks EGA in the NICHD Neonatal Research Network born during two post-surfactant era time periods (group I, 1991-1994, n=1408; group II, 1995-1998, n=1348). Perinatal and neonatal factors were compared, and group related mortality and DOMM risk were evaluated. RESULTS Mortality was higher for group I (63.1% v 56.7%; p=0.0006). Antenatal steroids (ANS) and antenatal antibiotics (AABX), surfactant (p<0.0001), and bronchopulmonary dysplasia (p=0.0008) were more prevalent in group II. In a regression model that controlled for basic and delivery factors only, mortality risk was greater for group I than for group II (odds ratio (OR) 1.4, 95% confidence interval (CI) 1.2 to 1.7); the addition of AABX and surfactant, or ANS (OR 0.97, 95% CI 0.79 to 1.2) to the model appeared to account for this difference. There was no difference in DOMM (86.8% v 88.4%; p=0.2), but risk was lower for group I in regression models that included ANS (OR 0.70, 95% CI 0.52 to 0.94). CONCLUSION Survival to discharge was more likely during the more recent period because of group differences in ANS, AABX, and surfactant. However, this treatment shift may reflect an overall more aggressive management approach. More consistent application of treatment has led to improving survival of <25 week EGA infants during the post-surfactant era, but possibly at the cost of greater risk of major in-hospital morbidities.
Collapse
Affiliation(s)
- S R Hintz
- Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University Medical Center, 750 Welch Road, Suite 315, Palo Alto, CA 94304, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Kelly WK, Galsky MD, Small EJ, Oh W, Chen I, Smith D, Martone L, Curley T, Delacruz A, Scher HI. Multi-institutional trial of the epothilone B analogue BMS-247550 with or without estramustine phosphate (EMP) in patients with progressive castrate-metastatic prostate cancer (PCMPC): Updated results. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4509] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. K. Kelly
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - M. D. Galsky
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - E. J. Small
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - W. Oh
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - I. Chen
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - D. Smith
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - L. Martone
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - T. Curley
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - A. Delacruz
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| | - H. I. Scher
- Memorial Sloan Kettering Cancer Center, New York, NY; University of California, San Francisco, CA; Dana-Farber Cancer Institute, Boston, MA; M. D. Anderson Cancer Center, Houston, TX; University of Michigan, Ann Arbor, MI
| |
Collapse
|
28
|
George D, Oh W, Gilligan T, Masson E, Souppart C, Wang Y, Ho Y, Lebwohl D, Laurent D, Kantoff P. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4689] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. George
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - W. Oh
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - T. Gilligan
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - E. Masson
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - C. Souppart
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - Y. Wang
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - Y. Ho
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - D. Lebwohl
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - D. Laurent
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| | - P. Kantoff
- Duke University, Durham, NC; Dana Farber Cancer Center, Boston, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Schering AG, Berlin, Germany
| |
Collapse
|
29
|
Shin TJ, Park HK, Lee SW, Lee B, Oh W, Kim JS, Baek S, Hwang YT, Kim HC, Ree M. Synthesis and characterization of new aromatic polyimides containing well-defined conjugation units. POLYM ENG SCI 2004. [DOI: 10.1002/pen.10104] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
30
|
Oh W, Hwang Y, Park Y, Ree M, Chu SH, Char K, Lee J, Kim S. Optical, dielectric and thermal properties of nanoscaled films of polyalkylsilsesquioxane composites with star-shaped poly(ε-caprolactone) and their derived nanoporous analogues. POLYMER 2003. [DOI: 10.1016/s0032-3861(03)00129-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
31
|
Abstract
Fracture of ceramic fixed-partial dentures (FPDs) tends to occur in the connector area because of stress concentrations. The objective of this study was to test the hypothesis that the radius of curvature at the gingival embrasure of the FPD connector significantly affects the fracture resistance of three-unit FPDs. Two three-dimensional finite element models (FEMs), representing two FPD connector designs, were created in a manner corresponding to that described in a previous experimental study (Oh, 2002). We performed fractographic analysis and FEM analyses based on CARES (NASA) post-processing software to determine the crack initiation site as well as to predict the characteristic strength, the location of peak stress concentrations, and the risk-of-rupture intensities. A good correlation was found between the experimentally measured failure loads and those predicted by FEM simulation analyses. Fractography revealed fracture initiation at the gingival embrasure, which confirms the numerically predicted fracture initiation site. For the designs tested, the radius of curvature at the gingival embrasure strongly affects the fracture resistance of FPDs.
Collapse
Affiliation(s)
- W Oh
- Department of Prosthodontics, College of Dentistry, Health Science Tower, PO Box 100435, University of Florida, Gainesville 32610-0435, USA.
| | | | | |
Collapse
|
32
|
Kim G, Shon J, Won H, Hyun J, Oh W. A study of methods to reduce groundwater contamination around the Kimpo landfill in Korea. Environ Technol 2002; 23:561-570. [PMID: 12088379 DOI: 10.1080/09593332508618394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
Abstract
Four different methods were studied to reduce the groundwater contamination around the Kimpo landfill in Korea by leakage of a leachate. The hydraulic parameters were measured for this study and then the groundwater flow and contaminant transport systems around the Kimpo landfill were simulated with MODFLOW and MT3D models. Both the method of establishing 5 sets of Radial Collector Well Laterals (RCWLs) within the landfill and a method utilizing the wells for dewatering condensed water brought about a 70% leachate elimination efficiency. Their construction costs were cheap, and the maximum concentrations of chloride and phenol in the leachate effluent were high. Meanwhile, a method establishing an interception wall to the 2nd layer at the cirumference of the landfill and 22 sets of RCWLs within it brought about a 92% leachate elimination efficiency. Its construction cost was expensive, and the maximum concentrations of chloride and phenol in the leachate effluent were low. A method of establishing an interception wall to the 3rd layer and 40 sets of RCWLs brought about a 97% leachate elimination efficiency. Its construction cost was the most expensive, and the maximum concentrations of chloride and phenol were low. Conclusively, a method of establishing 22 sets of RCWLs was evaluated as the most stable and economical option to reduce groundwater contamination concentration below drinking water standard.
Collapse
Affiliation(s)
- G Kim
- Korea Atomic Energy Research Institute, Yusong, Daejeon
| | | | | | | | | |
Collapse
|
33
|
Kim MH, Park TH, Yang DK, Oh W, Cha KS, Kim YD, Kim JS. Vasospasm in acute coronary syndrome: does ergonovine stress echocardiogram have a role? J Am Coll Cardiol 2002. [DOI: 10.1016/s0735-1097(02)81669-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
34
|
Stevenson DK, Fanaroff AA, Maisels MJ, Young BW, Wong RJ, Vreman HJ, MacMahon JR, Yeung CY, Seidman DS, Gale R, Oh W, Bhutani VK, Johnson LH, Kaplan M, Hammerman C, Nakamura H. Prediction of hyperbilirubinemia in near-term and term infants. J Perinatol 2001; 21 Suppl 1:S63-72; discussion S83-7. [PMID: 11803421 DOI: 10.1038/sj.jp.7210638] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
OBJECTIVE The purpose of this study was to determine whether end-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc), as a single measurement or in combination with serum total bilirubin (STB) measurements, can predict the development of hyperbilirubinemia during the first 7 days of life. METHODS From nine multinational clinical sites, 1370 neonates completed this cohort study from February 20, 1998 through February 22, 1999. Measurements of both ETCOc and STB were performed at 30+/-6 hours of life; STB also was measured at 96+/-12 hours and subsequently following a flow diagram based on a table of hours of age-specific STB. An infant was defined as hyperbilirubinemic if the hours of age-specific STB was greater than or equal to the 95th percentile as defined by the table at any time during the study. RESULTS A total of 120 (8.8%) of the enrolled infants became hyperbilirubinemic. Mean STB in breast-fed infants was 8.92+/-4.37 mg/dl at 96 hours versus 7.63+/-3.58 mg/dl in those fed formula only. The mean ETCOc at 30+/-6 hours for the total population was 1.48+/-0.49 ppm, whereas those of nonhyperbilirubinemic and hyperbilirubinemic infants were 1.45+/-0.47 and 1.81+/-0.59 ppm, respectively. Seventy-six percent (92 of 120) of hyperbilirubinemic infants had ETCOc greater than the population mean. An ETCOc greater than the population mean at 30+/-6 hours yielded a 13.0% positive predictive value (PPV) and a 95.8% negative predictive value (NPV) for STB > or =95th percentile. When infants with STB > or =95th percentile at <36 hours of age were excluded, the STB at 30+/-6 hours yielded a 16.7% PPV and a 98.1% NPV for STB >75th percentile. The combination of these two measurements at 30+/-6 hours (either ETCOc more than the population mean or STB >75th percentile) had a 6.4% PPV with a 99.0% NPV. CONCLUSIONS This prospective cohort study supports previous observations that measuring STB before discharge may provide some assistance in predicting an infant's risk for developing hyperbilirubinemia. The addition of an ETCOc measurement provides insight into the processes that contribute to the condition but does not materially improve the predictive ability of an hours of age-specific STB in this study population. The combination of STB and ETCOc as early as 30+/-6 hours may identify infants with increased bilirubin production (eg, hemolysis) or decreased elimination (conjugation defects) as well as infants who require early follow-up after discharge for jaundice or other clinical problems such as late anemia. Depending on the incidence of hyperbilirubinemia within an institution, the criteria for decision making should vary according to its unique population.
Collapse
Affiliation(s)
- D K Stevenson
- Department of Pediatrics, Lucile Salter Packard Children's Hospital, Stanford, CA 94305-5208, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
|
36
|
Vohr BR, Oh W, Stewart EJ, Bentkover JD, Gabbard S, Lemons J, Papile LA, Pye R. Comparison of costs and referral rates of 3 universal newborn hearing screening protocols. J Pediatr 2001; 139:238-44. [PMID: 11487750 DOI: 10.1067/mpd.2001.115971] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE To investigate the costs and referral rates of 3 universal newborn hearing screening programs: transient evoked otoacoustic emissions (TEOAE), automated auditory brainstem response (AABR), and a combination, two-step protocol in which TEOAE and AABR are used. STUDY DESIGN Clinical outcomes (referral rates) from 12,081 newborns at 5 sites were obtained by retrospective analysis. Prospective activity-based costing techniques (n = 1056) in conjunction with cost assumptions were used to analyze the costs based on an assumed annual birth rate of 1500 births. RESULTS Referral rates differed significantly among the 3 screening protocols (AABR, 3.21%; two-step, 4.67%; TEOAE, 6.49%; P <.01), with AABR achieving the best referral rate at discharge. Although AABR had the lowest referral rate at discharge and the highest pre-discharge costs, the total pre- and post-discharge costs per infant screened (AABR, $32.81; two-step, $33.05; TEOAE, $28.69) and costs per identified child (AABR, $16,405; two-step, $16,527; TEOAE, $14,347) were similar among programs. CONCLUSION Although AABR incurs higher costs during pre-discharge screening, it has lower referral rates than either the TEOAE or two-step program. As a result, the total costs of newborn hearing screening and diagnosis are similar among the 3 methods studied.
Collapse
Affiliation(s)
- B R Vohr
- Department of Pediatrics, Women and Infants Hospital, Brown University, Providence, Rhode Island 02905-2499, USA
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Hintz SR, Gaylord TD, Oh W, Fanaroff AA, Mele L, Stevenson DK, Nichd FT. Serum bilirubin levels at 72 hours by selected characteristics in breastfed and formula-fed term infants delivered by cesarean section. Acta Paediatr 2001; 90:776-81. [PMID: 11519981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/21/2023]
Abstract
UNLABELLED The present multicenter study analysed the relative impact of maternal and infant factors on serum bilirubin levels at 72 +/- 12 h in exclusively breastfed vs formula-fed term infants. End-tidal carbon monoxide levels corrected for ambient air (ETCOc), an index of bilirubin production, were measured in exclusively breastfed (B = 66) or formula-fed (F = 210) term infants at 2-8 h of age. Inclusion criteria included cesarean section to ensure a 3 d hospitalization, birthweight > or = 2,500 g, gestational age >37 wk and absence of any illness. The ETCOc for B infants and F infants did not differ significantly (1.3 +/- 0.7 ppm vs 1.3 +/- 0.8 ppm). The serum bilirubin level at 72 +/- 12 h was significantly higher in B infants than in F infants (8.5 +/- 3.4mg dl(-1) vs 6.7 +/- 3.4mg dl(-1) p < 0.001), as was the percentage weight loss from birthweight. Serum bilirubin levels were significantly higher in infants who were male, who did not have meconium-stained amniotic fluid, and in those whose mothers were insulin-dependent diabetics or hypertensive. There was no difference between groups in the need for phototherapy or exchange transfusion. CONCLUSION Although higher bilirubin levels were observed in group B at 72 +/- 12 h compared with group F, this finding was not of clinical or therapeutic consequence in this study. The lack of difference in ETCOc between the groups may be a factor of the timing of ETCOc measurement in this study, or may suggest that early increased bilirubin production is not a significant contributor to jaundice observed in exclusively breastfed infants. Key words: bilirubin, breastfeeding, jaundice
Collapse
Affiliation(s)
- S R Hintz
- Division of Neonatal and Developmental Medicine, Stanford University, Palo Alto, California 94304, USA.
| | | | | | | | | | | | | |
Collapse
|
38
|
Stevenson DK, Fanaroff AA, Maisels MJ, Young BW, Wong RJ, Vreman HJ, MacMahon JR, Yeung CY, Seidman DS, Gale R, Oh W, Bhutani VK, Johnson LH, Kaplan M, Hammerman C, Nakamura H. Prediction of hyperbilirubinemia in near-term and term infants. Pediatrics 2001; 108:31-9. [PMID: 11433051 DOI: 10.1542/peds.108.1.31] [Citation(s) in RCA: 151] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVE The purpose of this study was to determine whether end-tidal carbon monoxide (CO) corrected for ambient CO (ETCOc), as a single measurement or in combination with serum total bilirubin (STB) measurements, can predict the development of hyperbilirubinemia during the first 7 days of life. METHODS From 9 multinational clinical sites, 1370 neonates completed this cohort study from February 20, 1998, through February 22, 1999. Measurements of both ETCOc and STB were performed at 30 +/- 6 hours of life; STB also was measured at 96 +/- 12 hours and subsequently following a flow diagram based on a table of hours of age-specific STB. An infant was defined as hyperbilirubinemic if the hours of age-specific STB was greater than or equal to the 95th percentile as defined by the table at any time during the study. RESULTS A total of 120 (8.8%) of the enrolled infants became hyperbilirubinemic. Mean STB in breastfed infants was 8.92 +/- 4.37 mg/dL at 96 hours versus 7.63 +/- 3.58 mg/dL in those fed formula only. The mean ETCOc at 30 +/- 6 hours for the total population was 1.48 +/- 0.49 ppm, whereas those of nonhyperbilirubinemic and hyperbilirubinemic infants were 1.45 +/- 0.47 ppm and 1.81 +/- 0.59 ppm, respectively. Seventy-six percent (92 of 120) of hyperbilirubinemic infants had ETCOc greater than the population mean. An ETCOc greater than the population mean at 30 +/- 6 hours yielded a 13.0% positive predictive value (PPV) and a 95.8% negative predictive value (NPV) for STB >/=95th percentile. When infants with STB >95th percentile at <36 hours of age were excluded, the STB at 30 +/- 6 hours yielded a 16.7% PPV and a 98.1% NPV for STB >75th percentile. The combination of these 2 measurements at 30 +/- 6 hours (either ETCOc more than the population mean or STB >75th percentile) had a 6.4% PPV with a 99.0% NPV. Conclusions. This prospective cohort study supports previous observations that measuring STB before discharge may provide some assistance in predicting an infant's risk for developing hyperbilirubinemia. The addition of an ETCOc measurement provides insight into the processes that contribute to the condition but does not materially improve the predictive ability of an hours of age-specific STB in this study population. The combination of STB and ETCOc as early as 30 +/- 6 hours may identify infants with increased bilirubin production (eg, hemolysis) or decreased elimination (conjugation defects) as well as infants who require early follow-up after discharge for jaundice or other clinical problems such as late anemia. Depending on the incidence of hyperbilirubinemia within an institution, the criteria for decision making should vary according to its unique population.
Collapse
Affiliation(s)
- D K Stevenson
- Department of Pediatrics, Lucile Salter Packard Children's Hospital, Stanford, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Burgess GH, Oh W, Brann BS, Brubakk AM, Stonestreet BS. Effects of phenobarbital on cerebral blood flow velocity after endotracheal suctioning in premature neonates. Arch Pediatr Adolesc Med 2001; 155:723-7. [PMID: 11386965 DOI: 10.1001/archpedi.155.6.723] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVE To examine the effect of phenobarbital administration on anterior cerebral artery blood flow velocity before and after endotracheal suctioning in premature neonates. DESIGN Transcutaneous PO(2) (TcPO(2)), heart rate, mean arterial blood pressure (MABP), and Doppler velocimeter blood flow of the left anterior cerebral artery were measured before and immediately after 3 consecutive endotracheal suctioning procedures in premature neonates. Intravenous phenobarbital (20 mg/kg) was administered immediately after the first procedure. SETTING Neonatal intensive care unit. PATIENTS Nine neonates with a mean birth weight of 807 g (range, 620-1060 g) and a mean gestational age of 27 weeks (range, 25-30 weeks) were studied at age 8 to 12 hours. RESULTS Transcutaneous PO(2) decreased in response to endotracheal suctioning at each of the suctioning procedures before and after phenobarbital was given (P<.001). Changes in heart rate were not observed. There were increases in MABP and area under the velocity curve (AUVC) per minute in response to endotracheal suctioning before but not after phenobarbital administration (P=.046). Use of phenobarbital lowered the overall peak systolic blood flow velocity in response to endotracheal suctioning (P =.02, analysis of variance, interactions for the effect of phenobarbital therapy on the response to suctioning). Changes in end-diastolic blood flow velocity were not observed. There were decreases in the differences before and after endotracheal suctioning for MABP at 2 and 4 hours and for AUVC and peak systolic blood flow velocity 4 hours after phenobarbital was given (P =.04). CONCLUSIONS In very low-birth-weight neonates, endotracheal suctioning is associated with decreases in TcPO(2) and increases in MABP and AUVC. Treatment with phenobarbital attenuates the increases in MABP and AUVC but not the decreases in TcPO(2) after endotracheal suctioning.
Collapse
Affiliation(s)
- G H Burgess
- Department of Pediatrics, Brown University School of Medicine, Women and Infants Hospital of Rhode Island, 101 Dudley St, Providence, RI 02905-240, USA.
| | | | | | | | | |
Collapse
|
40
|
Green WT, Watts HG, Panagakos P, Oh W, Wilson RE, Banks HH. Radiocalcium-47 kinetic studies in the dog. Intrinsic variability under standard conditions; effects of thyroparathyroidectomy; effects of parathormone and triiodothyronine. Clin Orthop Relat Res 2001; 61:154-63. [PMID: 5704404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
41
|
Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll BJ. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 2001; 344:95-101. [PMID: 11150359 DOI: 10.1056/nejm200101113440203] [Citation(s) in RCA: 393] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Early administration of high doses of dexamethasone may reduce the risk of chronic lung disease in premature infants but can cause complications. Whether moderate doses would be as effective but safer is not known. METHODS We randomly assigned 220 infants with a birth weight of 501 to 1000 g who were treated with mechanical ventilation within 12 hours after birth to receive dexamethasone or placebo with either routine ventilatory support or permissive hypercapnia. The dexamethasone was administered within 24 hours after birth at a dose of 0.15 mg per kilogram of body weight per day for three days, followed by a tapering of the dose over a period of seven days. The primary outcome was death or chronic lung disease at 36 weeks' postmenstrual age. RESULTS The relative risk of death or chronic lung disease in the dexamethasone-treated infants, as compared with those who received placebo, was 0.9 (95 percent confidence interval, 0.8 to 1.1). Since the effect of dexamethasone treatment did not vary according to the ventilatory approach, the two dexamethasone groups and the two placebo groups were combined. The infants in the dexamethasone group were less likely than those in the placebo group to be receiving oxygen supplementation 28 days after birth (P=0.004) or open-label dexamethasone (P=0.01), were more likely to have hypertension (P<0.001), and were more likely to be receiving insulin treatment for hyperglycemia (P=0.02). During the first 14 days, spontaneous gastrointestinal perforation occurred in a larger proportion of infants in the dexamethasone group (13 percent, vs. 4 percent in the placebo group; P=0.02). The dexamethasone-treated infants had a lower weight (P=0.02) and a smaller head circumference (P=0.04) at 36 weeks' postmenstrual age. CONCLUSIONS In preterm infants, early administration of dexamethasone at a moderate dose has no effect on death or chronic lung disease and is associated with gastrointestinal perforation and decreased growth.
Collapse
Affiliation(s)
- A R Stark
- Brigham and Women's Hospital, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001; 19:44-53. [PMID: 11134194 DOI: 10.1200/jco.2001.19.1.44] [Citation(s) in RCA: 151] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To determine the safety and activity of weekly paclitaxel in combination with estramustine and carboplatin (TEC) in patients with advanced prostate cancer. PATIENTS AND METHODS In a dose-escalation study, patients with advanced prostate cancer were administered paclitaxel (weekly 1-hour infusions of 60 to 100 mg/m(2)), oral estramustine (10 mg/kg), and carboplatin (area under the curve, 6 mg/mL-min every 4 weeks). Paclitaxel levels were determined 0, 30, 60, 90, and 120 minutes and 18 hours after infusion, and a concentration-time curve was estimated. Once a safe dose was established, a multi-institutional phase II trial was conducted in patients with progressive androgen-independent disease. RESULTS Fifty-six patients with progressive androgen-independent disease were treated for a median of four cycles. The dose of paclitaxel was escalated from 60 to 100 mg/m(2) without the occurrence of DLT. Posttherapy decreases in serum prostate-specific antigen levels of 50%, 80%, and 90% were seen in 67%, 48%, and 39% (95% confidence interval, 55% to 79%, 35% to 61%, 26% to 52%) of the patients, respectively. Of the 33 patients with measurable disease, two (6%) had a complete response and 13 (39%) had a partial response. The overall median time to progression was 21 weeks, and the median survival time for all patients was 19.9 months. Major grade 3 or 4 adverse effects were thromboembolic disease (in 25% of patients), hyperglycemia (in 38%), and hypophosphatemia (in 42%). Significant leukopenia, thrombocytopenia, and peripheral neuropathy were not observed. CONCLUSION TEC has significant antitumor activity and is well tolerated in patients with progressive androgen-independent prostate cancer.
Collapse
Affiliation(s)
- W K Kelly
- Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, Verter J, Temprosa M, Wright LL, Ehrenkranz RA, Fanaroff AA, Stark A, Carlo W, Tyson JE, Donovan EF, Shankaran S, Stevenson DK. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1. [PMID: 11134465 DOI: 10.1542/peds.107.1.e1] [Citation(s) in RCA: 788] [Impact Index Per Article: 34.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
OBJECTIVES To determine the mortality and morbidity for infants weighing 401 to 1500 g (very low birth weight [VLBW]) at birth by gestational age, birth weight, and gender. STUDY DESIGN Perinatal data were collected prospectively on an inborn cohort from January 1995 through December 1996 by 14 participating centers of the National Institute of Child Health and Human Development Neonatal Research Network and were compared with the corresponding data from previous reports. Sociodemographic factors, perinatal events, and the neonatal course to 120 days of life, discharge, or death were evaluated. RESULTS Eighty four percent of 4438 infants weighing 501 to 1500 g at birth survived until discharge to home or to a long-term care facility (compared with 80% in 1991 and 74% in 1988). Survival to discharge was 54% for infants 501 to 750 g at birth, 86% for those 751 to 1000 g, 94% for those 1001 to 1250 g, and 97% for those 1251 to 1500g. The incidence of chronic lung disease (CLD; defined as receiving supplemental oxygen at 36 weeks' postmenstrual age; 23%), proven necrotizing enterocolitis (NEC; 7%), and severe intracranial hemorrhage (ICH; grade III or IV; 11%) remained unchanged between 1991 and 1996. Furthermore, 97% of all VLBW infants and 99% of infants weighing <1000 g at birth had weights less than the 10th percentile at 36 weeks' postmenstrual age. Mortality for 195 infants weighing 401 to 500 g was 89%, with nearly all survivors developing CLD. Mortality in infants weighing 501 to 600 g was 71%; among survivors, 62% had CLD, 35% had severe ICH, and 15% had proven NEC. CONCLUSIONS Survival for infants between 501 and 1500 g at birth continued to improve, particularly for infants weighing <1000 g at birth. This improvement in survival was not associated with an increase in major morbidities, because the incidence of CLD, proven NEC, and severe ICH did not change. However, poor postnatal growth remains a major concern, occurring in 99% of infants weighing <1000 g at birth. Mortality and major morbidity (CLD, severe ICH, and NEC) remain high for the smallest infants, particularly those weighing <600 g at birth.
Collapse
Affiliation(s)
- J A Lemons
- Indiana University, Indianapolis, Indiana, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
OBJECTIVE The purpose of this prospective longitudinal study was to examine neurocognitive and school performance outcomes of low birth weight infants with reference to neonatal morbidity and socioeconomic status. We further evaluated the cognition and school performance based on their neurologic status at the time of assessment. METHODS One hundred eighty-eight children (39 healthy full-term and 149 preterm infants) were classified into 4 subgroups based on their neonatal medical status: healthy, sick (without neurologic complications), small for gestational age, and neurologically compromised infants. Neurologic status was classified as normal, suspect, or abnormal at hospital discharge, 18 months, 30 months, 4 years, and 8 years of age. Socioeconomic status, cognitive, and school performances were assessed. RESULTS Neurologically, both full-term and healthy preterm groups did well during the 8-year period. There were significant fluctuations between suspect and abnormal neurologic classifications among the 3 preterm groups with neonatal complications. Preterms with neurologic abnormality during the neonatal period did the poorest with 45% of the group remaining abnormal at 8 years of age. Children who were neurologically normal had higher cognitive scores at ages 4 and 8 than those categorized as suspect or abnormal. Preterm infants with neurologic abnormality required significantly more academic resources in the school. Reading and math achievement scores were the lowest for the preterm groups classified as neurologically suspect or abnormal. CONCLUSIONS Neonatal morbidities exert a significant impact in neurologic outcomes among preterm children during the 8 years of assessment. Compromised neurologic status adversely affects cognitive and school performances. Neonatal medical status is an important variable indicating neurocognitive and school performance outcomes in low birth weight infants.
Collapse
Affiliation(s)
- M M McGrath
- University of Rhode Island, College of Nursing, Kingston, Rhode Island, USA
| | | | | | | |
Collapse
|
45
|
Stevenson DK, Verter J, Fanaroff AA, Oh W, Ehrenkranz RA, Shankaran S, Donovan EF, Wright LL, Lemons JA, Tyson JE, Korones SB, Bauer CR, Stoll BJ, Papile LA. Sex differences in outcomes of very low birthweight infants: the newborn male disadvantage. Arch Dis Child Fetal Neonatal Ed 2000; 83:F182-5. [PMID: 11040165 PMCID: PMC1721180 DOI: 10.1136/fn.83.3.f182] [Citation(s) in RCA: 314] [Impact Index Per Article: 13.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
OBJECTIVE To determine the differences in short term outcome of very low birthweight infants attributable to sex. METHODS Boys and girls weighing 501-1500 g admitted to the 12 centres of the National Institute of Child Health and Human Development Neonatal Research Network were compared. Maternal information and perinatal data were collected from hospital records. Infant outcome was recorded at discharge, at 120 days of age if the infant was still in hospital, or at death. Best obstetric estimate based on the last menstrual period, standard obstetric factors, and ultrasound were used to assign gestational age in completed weeks. Data were collected on a cohort that included 3356 boys and 3382 girls, representing all inborn births from 1 May 1991 to 31 December 1993. RESULTS Mortality for boys was 22% and that for girls 15%. The prenatal and perinatal data indicate few differences between the sex groups, except that boys were less likely to have been exposed to antenatal steroids (odds ratio (OR) = 0.80) and were less stable after birth, as reflected in a higher percentage with lower Apgar scores at one and five minutes and the need for physical and pharmacological assistance. In particular, boys were more likely to have been intubated (OR = 1.16) and to have received resuscitation medication (OR = 1.40). Boys had a higher risk (OR > 1.00) for most adverse neonatal outcomes. Although pulmonary morbidity predominated, intracranial haemorrhage and urinary tract infection were also more common. CONCLUSIONS Relative differences in short term morbidity and mortality persist between the sexes.
Collapse
Affiliation(s)
- D K Stevenson
- Department of Pediatrics, Stanford University, Palo Alto, CA 94305-5119, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
BACKGROUND The aim of this study was to determine the safety and activity of vinorelbine in combination with estramustine in men with androgen-independent metastatic prostate cancer. METHODS Twenty-five men with androgen-independent metastatic prostate cancer were treated with the combination of vinorelbine and estramustine. Vinorelbine 25 mg/m(2) was administered by intravenous bolus on Days 1 and 8. Estramustine 140 mg was administered three times a day by mouth on Days 1 through 14. Treatment was repeated every 21 days. RESULTS A total of 132 cycles of treatment were administered. The median number of cycles per patient was 5 (range: 1-16). Mild Grade 1 or 2 gastrointestinal toxicity and fatigue were the most common adverse effects. Hematologic toxicity was minimal. Treatment resulted in a sustained > 50% decrease in serum prostate-specific antigen (PSA) in 6 of 25 patients (24% of patients; 95% confidence interval (CI) 9-45%). The median duration of PSA response was 10 weeks (range: 3-39 weeks). Of the five men with bidimensionally measurable disease, none achieved a complete or partial response. There were no documented improvements in post-treatment bone scans. Median overall survival time was 14.1 months. CONCLUSIONS The combination of vinorelbine and estramustine is a well-tolerated and modestly active regimen in men with androgen-independent metastatic prostate cancer.
Collapse
Affiliation(s)
- M R Smith
- Massachusetts General Hospital, Boston, Massachusetts, USA.
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A 2000; 97:10990-5. [PMID: 10984506 PMCID: PMC27136 DOI: 10.1073/pnas.180329197] [Citation(s) in RCA: 341] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear hormone receptor that plays a key role in the differentiation of adipocytes. Activation of this receptor in liposarcomas and breast and colon cancer cells also induces cell growth inhibition and differentiation. In the present study, we show that PPARgamma is expressed in human prostate adenocarcinomas and cell lines derived from these tumors. Activation of this receptor with specific ligands exerts an inhibitory effect on the growth of prostate cancer cell lines. Further, we show that prostate cancer and cell lines do not have intragenic mutations in the PPARgamma gene, although 40% of the informative tumors have hemizygous deletions of this gene. Based on our preclinical data, we conducted a phase II clinical study in patients with advanced prostate cancer using troglitazone, a PPARgamma ligand used for the treatment of type 2 diabetes. Forty-one men with histologically confirmed prostate cancer and no symptomatic metastatic disease were treated orally with troglitazone. An unexpectedly high incidence of prolonged stabilization of prostate-specific antigen was seen in patients treated with troglitazone. In addition, one patient had a dramatic decrease in serum prostate-specific antigen to nearly undetectable levels. These data suggest that PPARgamma may serve as a biological modifier in human prostate cancer and its therapeutic potential in this disease should be further investigated.
Collapse
Affiliation(s)
- E Mueller
- Dana-Farber Cancer Institute and Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Goldstein M, Rehan VK, Oh W, Stonestreet BS. Cerebral and intestinal perfusion and metabolism in normocythemic hyperviscous hypoxic newborn pigs. J Appl Physiol (1985) 2000; 88:2107-15. [PMID: 10846024 DOI: 10.1152/jappl.2000.88.6.2107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
We studied the effects of hypoxia on cerebral cortical and intestinal perfusion and metabolism in normocythemic hyperviscous newborn pigs. Seven pigs were made hyperviscous by an injection of cryoprecipitate, increasing viscosity from 5.8 +/- 0.9 to 9.0 +/- 1. 2 (SD) cycles/s. Six normoviscous pigs received 0.9% NaCl. Reducing the inspired O(2) decreased the arterial O(2) content (Ca(O(2))) from 9.5 +/- 1.6 to 3.6 +/- 1.3 ml O(2)/100 ml. Increases in brain and decreases in gastrointestinal blood flow at the lower Ca(O(2)) values were similar between the groups. During hypoxia, blood flow to stomach, distal intestinal mucosa, and large intestines was lower (-50, -23, and -28%, respectively) in the hyperviscous than normoviscous group. At the lower Ca(O(2)) values, cerebral cortical vascular resistance decreased in both groups and intestinal vascular resistance increased (+257%) in the hyperviscous but not in the normoviscous group. During hypoxia, systemic oxygen delivery decreased, extraction increased, and uptake did not change; cerebral cortical O(2) delivery, extraction, and uptake did not change; and intestinal O(2) delivery decreased, extraction increased, and uptake did not change in both groups. Our study demonstrated that 1) during hypoxia, increases in systemic O(2) extraction compensated for decreases in delivery and systemic uptake did not change; vasodilation sustained cerebral cortical O(2) delivery and preserved metabolism; increases in intestinal oxygen extraction offset decreases in delivery and uptake was preserved; and 2) nonpolycythemic hyperviscosity did not have a major influence on cardiovascular or metabolic responses to hypoxia, except for modest effects on intestinal resistance and perfusion to certain gastrointestinal regions. We conclude that, under normocythemic conditions, a moderate increase in viscosity does not have a major impact on hemodynamic or metabolic adjustments to hypoxia in newborn pigs.
Collapse
Affiliation(s)
- M Goldstein
- Department of Pediatrics, Women and Infants' Hospital of Rhode Island, Brown University School of Medicine, Providence 02905, USA
| | | | | | | |
Collapse
|
49
|
Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18:1921-7. [PMID: 10784633 DOI: 10.1200/jco.2000.18.9.1921] [Citation(s) in RCA: 184] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To assess the activity and toxicity of the combination of gemcitabine and cisplatin in the treatment of chemotherapy-naive patients with metastatic urothelial cancer. PATIENTS AND METHODS Forty-six patients with measurable stage IV carcinoma of the urothelium were enrolled onto this trial. Gemcitabine 1,000 mg/m(2) was administered intravenously for 30 to 60 minutes on days 1, 8, and 15 of each 28-day cycle. Cisplatin was administered after gemcitabine on day 1 of each cycle. The first 11 patients received an initial cisplatin dose of 100 mg/m(2). Due to the hematologic toxicity observed in several of these patients, the dose was reduced to 75 mg/m(2) in the remaining 35 patients. Patients were treated with six cycles, unless disease progression or severe toxicity necessitated earlier discontinuation. RESULTS Ten of the 46 patients achieved a complete response and nine showed a partial response. The overall response rate was 41%. The median time to treatment failure was 5.5 months. The median survival was 14.3 months, and the 1-year survival probability was 54%. Most of the toxicities were hematologic and, in general, easily manageable. CONCLUSION Gemcitabine plus cisplatin is active in the treatment of metastatic urothelial cancer in chemotherapy-naive patients and has an acceptable clinical safety profile. Studies are under way to further define the place of gemcitabine in combination with other chemotherapeutic agents in the treatment of metastatic urothelial cancer.
Collapse
Affiliation(s)
- D Kaufman
- Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston, MA 02114, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Antiandrogens competitively inhibit ligand binding to the androgen receptor (AR), and are used therapeutically in prostate cancer patients. The AR functions as a ligand dependent transcription factor that transduces androgen binding into increased transcription of androgen dependent genes. AR blockade induces programmed cell death in the vast majority of malignant and benign prostate cancer cells that have not previously been exposed to androgen ablation. The antiandrogens are divided structurally into the steroidal and non steroidal agents. The biological effects of the steroidal versus nonsteroidal agents are distinguished by differences in their effects on serum testosterone levels, and by their activity at receptors other than the androgen receptor. There is extensive clinical experience in the palliative and curative therapy of prostate cancer using antiandrogens as monotherapy or antiandrogens in combination with luteinizing hormone agonists or surgical castration. Prolonged therapy with antiandrogens selects for mutations in the AR that change the AR ligand specificity and permits stimulation by ligands that are usually inhibitory. These mutations give insight into one of the means by which prostate cancer progresses despite antiandrogen therapy, and also helps to explain the antiandrogen withdrawal syndrome. Areas of active research that may affect the future use of antiandrogens include the ongoing evaluation of antiandrogens in combination with 5 alpha reductase inhibitors to achieve AR blockade without inducing castrate testosterone levels. There is also interest in developing selective androgen receptor modulators (SARM) that can achieve AR blockade without causing the increased testosterone levels produced by the nonsteroidal antiandrogens currently in use.
Collapse
Affiliation(s)
- P Reid
- Lank Center for Genitourinary Oncology, Dana Farber-Partners Cancer Care, Boston, MA 02115, USA
| | | | | |
Collapse
|